During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation
Lyon, France, March 23rd, 2026, 6:00pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announced that Florent Malard, MD, PhD, hematology professor at Saint‑Antoine Hospital and Sorbonne University, presented the final results from the Phase 3 ARES single‑arm pivotal trial evaluating MaaT013 in acute Graft‑versus‑Host Disease (aGvHD).
The presentation took place during the Presidential Plenary Session at the 2026 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Madrid, Spain. MaaT013 is currently under review by the European Medicines Agency (EMA) following the submission of a Marketing Authorization Application in June 2025, with a decision expected mid-2026, as previously disclosed.
